Evotec, Takeda in RNA Targeting Drug Discovery and Development Alliance

 

• EVOTEC LEVERAGES ITS PROPRIETARY SMALL MOLECULE RNA TARGETING PLATFORM AGAINST MULTIPLE RNA TARGETS ACROSS TAKEDA'S KEY INDICATIONS
• EVOTEC RECEIVES RESEARCH FUNDING AND IS ELIGIBLE FOR SUCCESS-BASED MILESTONES AND TIERED ROYALTIES

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited ("Takeda") with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.

Evotec and Takeda will jointly identify and develop small molecules targeting a range of RNA targets aligned with Takeda's research and development areas. The collaboration will leverage Evotec's extensive RNA targeting platform to optimally identify promising RNA sequences to target with small molecule ligands that can be developed into potentially first-in-class therapeutics.

Under the terms of the agreement, Evotec will receive significant research funding and will be eligible to receive discovery, pre-clinical, clinical, commercial and sales milestone payments of up to US$ 160 m per programme. Additionally, Evotec is entitled to tiered royalties on net sales of any products resulting from the collaboration.

https://www.streetinsider.com/Corporate+News/Evotec+and+Takeda+%28TAK%29+Enter+Strategic+RNA+Targeting+Drug+Discovery+and+Development+Alliance/18156662.html